In Table 1, we found that there was a higher expression level of RAD51B in NSCLC patients with male, squamous cell carcinoma, EGFR mutation, and no KRAS mutation than the reference groups (all P<0.05). The gene discussed is KRAS; the disease is non-small cell lung carcinoma.